Latest Royalties News

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Livium Ltd reports a maiden profit at its battery recycling arm Envirostream, advances its lithium extraction joint venture with Mineral Resources, and secures a $30 million grant for its lithium ferro phosphate demonstration plant.

Carbonxt Group Limited reported a 7.1% revenue increase to $16.2 million in FY25 alongside a 16.7% reduction in net loss, while progressing its Kentucky liquid-phase activated carbon facility and navigating ongoing liquidity challenges.

Jupiter Mines Limited reported a modest rise in net profit to $40.1 million for FY2025, supported by strong joint venture earnings and increased marketing fees. The company declared a final dividend as manganese prices stabilized after early-year volatility.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.